VCYT Veracyte Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VCYT

Price (delayed)

$49.93

Market cap

$3.98B

P/E Ratio

44.98

Dividend/share

N/A

EPS

$1.11

Enterprise value

$3.76B

?
Relative Growth: Rel. Growth: 87
Relative Strength: Rel. Strength: 84
Relative Valuation: Rel. Valuation: 45
Relative Profitability: Rel. Profitability: 90

Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other ...

Highlights
Veracyte's net income has surged by 166% YoY and by 33% QoQ
The EPS has surged by 158% year-on-year and by 32% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.veracyte.com
Peers: MYGN CYTK

Key stats

What are the main financial stats of VCYT

VCYT stock price

How has the Veracyte stock price performed over time
Intraday
2.55%
1 week
4.04%
1 month
49.27%
1 year
82.96%
YTD
18.6%
QTD
55.01%

Financial performance

How have Veracyte's revenue and profit performed over time
Revenue
$541.74M
Gross profit
$384.18M
Operating income
$77.52M
Net income
$88.01M
Gross margin
70.9%
Net margin
16.2%
The operating margin has soared by 180% YoY and by 28% from the previous quarter
Veracyte's net income has surged by 166% YoY and by 33% QoQ
The net margin has soared by 128% YoY and by 27% from the previous quarter
The operating income has grown by 34% from the previous quarter

Price vs fundamentals

How does VCYT's price correlate with its fundamentals

Growth

What is Veracyte's growth rate over time

Valuation

What is Veracyte stock price valuation
VCYT P/E details
P/E
44.98
P/B
2.95
P/S
7.33
EV/EBIT
41.42
EV/EBITDA
32.67
EV/Sales
6.94
The EPS has surged by 158% year-on-year and by 32% since the previous quarter
The stock's price to earnings (P/E) is 28% less than its last 4 quarters average of 61.1
The P/B is 52% above the 5-year quarterly average of 1.9 and 37% above the last 4 quarters average of 2.1
The equity has grown by 13% YoY and by 2.7% from the previous quarter
The P/S is 35% above the last 4 quarters average of 5.3 and 3.6% above the 5-year quarterly average of 6.9
Veracyte's revenue has increased by 17% YoY and by 4.8% QoQ

Efficiency

How efficient is Veracyte business performance
The company's return on equity has surged by 146% YoY and by 30% QoQ
The ROA has soared by 142% YoY and by 29% from the previous quarter
The return on sales has surged by 121% year-on-year and by 27% since the previous quarter
VCYT's return on invested capital has surged by 79% year-on-year and by 25% since the previous quarter

Dividends

What is VCYT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VCYT.

Financial health

How did Veracyte financials performed over time
The company's quick ratio has surged by 92% YoY and by 14% QoQ
The company's current ratio has surged by 83% YoY and by 14% QoQ
The debt is 97% less than the equity
VCYT's debt to equity is down by 25% year-on-year
The debt has contracted by 22% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.